AGREEMENT PRESS RELEASE
Mylan Agrees to Pay $465 Million to Resolve False Claims Act Liability
Published by the United States Department of Justice | View article on www.justice.gov
BOSTON - The U.S. Attorney's Office announced today that pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve allegations that they violated the False Claims Act by knowingly misclassifying EpiPen, a branded epinephrine auto-injector drug, as a generic drug to avoid paying rebates owed to Medicaid. Mylan Inc. and Mylan Specialty L.P. are both wholly owned subsidiaries of Mylan N.V., a Dutch-registered entity headquartered in Canonsburg, Penn.
ENFORCEMENT ACTIONS
Pharmaceutical Company Mylan to Pay $20.3 Million for Underpaying Rebates on Epipens for Masshealth Members
Penalty Amount: $0
Filed under: State Enforcement Agencies
BOSTON - Pharmaceutical company Mylan will pay a total of $20.3 million to the Massachusetts Medicaid program (MassHealth) to resolve allegations that it knowingly underpaid rebates owed to the Medicaid program for EpiPens dispensed to MassHealth members, Attorney General Maura Healey announced today.